Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Merrimack Pharmaceuticals, Inc is a biotechnology business based in the US. Merrimack Pharmaceuticals shares (MACK) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$8.26|
|52-week range||USD$1.49 - USD$4.7|
|50-day moving average||USD$3.8309|
|200-day moving average||USD$3.657|
|Wall St. target price||USD$4|
|Dividend yield||N/A (57.71%)|
|Earnings per share (TTM)||USD$0.1|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||10.13%|
|1 month (2020-12-16)||19.19%|
|3 months (2020-10-15)||113.44%|
|6 months (2020-07-15)||157.32%|
|1 year (2020-01-15)||164.74%|
|2 years (2019-01-15)||71.37%|
|3 years (2018-01-12)||10.74|
|5 years (2016-01-15)||34.09%|
Valuing Merrimack Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merrimack Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merrimack Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Merrimack Pharmaceuticals shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merrimack Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merrimack Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merrimack Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$134,000.
The EBITDA is a measure of a Merrimack Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Gross profit TTM||USD$-9,100,000|
|Return on assets TTM||-18.08%|
|Return on equity TTM||-14.08%|
|Market capitalisation||USD$53.7 million|
TTM: trailing 12 months
There are currently 530,342 Merrimack Pharmaceuticals shares held short by investors – that's known as Merrimack Pharmaceuticals's "short interest". This figure is 6.5% up from 497,943 last month.
There are a few different ways that this level of interest in shorting Merrimack Pharmaceuticals shares can be evaluated.
Merrimack Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Merrimack Pharmaceuticals shares currently shorted divided by the average quantity of Merrimack Pharmaceuticals shares traded daily (recently around 24564.242704956). Merrimack Pharmaceuticals's SIR currently stands at 21.59. In other words for every 100,000 Merrimack Pharmaceuticals shares traded daily on the market, roughly 21590 shares are currently held short.
However Merrimack Pharmaceuticals's short interest can also be evaluated against the total number of Merrimack Pharmaceuticals shares, or, against the total number of tradable Merrimack Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merrimack Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Merrimack Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0485% of the tradable shares (for every 100,000 tradable Merrimack Pharmaceuticals shares, roughly 49 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Merrimack Pharmaceuticals.
Find out more about how you can short Merrimack Pharmaceuticals stock.
Dividend payout ratio: 499.74% of net profits
Recently Merrimack Pharmaceuticals has paid out, on average, around 499.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 57.71% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merrimack Pharmaceuticals shareholders could enjoy a 57.71% return on their shares, in the form of dividend payments. In Merrimack Pharmaceuticals's case, that would currently equate to about $N/A per share.
Merrimack Pharmaceuticals's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Merrimack Pharmaceuticals's most recent dividend payout was on 23 December 2019. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2019 (the "ex-dividend date").
Merrimack Pharmaceuticals's shares were split on a 1271:1000 basis on 6 September 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1271 shares. This wouldn't directly have changed the overall worth of your Merrimack Pharmaceuticals shares – just the quantity. However, indirectly, the new 21.3% lower share price could have impacted the market appetite for Merrimack Pharmaceuticals shares which in turn could have impacted Merrimack Pharmaceuticals's share price.
Over the last 12 months, Merrimack Pharmaceuticals's shares have ranged in value from as little as $1.49 up to $4.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merrimack Pharmaceuticals's is 2.544. This would suggest that Merrimack Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is based in Cambridge, Massachusetts.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.